Memento Medicines launches with focus on ophthalmology
AI Briefing
- • Memento Medicines Inc. launches with $93 million series A financing.
- • The company focuses on ophthalmology, particularly retinal diseases.
- • A lead program has been licensed for commercialization.
Context
Memento Medicines Inc has launched with a series A financing of $93 million. The company has also licensed a lead program for retinal diseases.
The launch of Memento Medicines and its focus on ophthalmology, specifically retinal diseases, marks the company's entry into the field.
Advertisement